Recently a report by Baldacchino et al., demonstrated that deregulation of PP2A is a common event in breast cancer and a particular subset of patients with suppressed PP2A activity are potentially eligible for treatment using therapies which target the PI3K/AKT/mTOR pathway such as phosphatase activators like FTY720 [59]. This evidence concerns the gene PTPA and breast cancer.